Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Interessting

<< Previous

Bullboard Posts

Next >>

Comment by tylerreddickon May 22, 2024 4:12pm

99 Views

Post# 36052717

RE:Interessting

Nice catch.
Just highlights how pathetic SBM's marketing of 1067 has been, choosing a loser like R&F in the beginning.
Coming out of the Covid lockup, women were desperate to look their best, and if we had our spot treatment on the market then, we could have very well been making good money already, instead of begging for a few bucks to keep the lights on.

Great science, lousy management.

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant